Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance

Horizon Therapeutics (HZNP) Tops Q4 EPS by 22c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus

Horizon Therapeutics (NASDAQ: HZNP) reported Q4 EPS of $1.28, $0.22 better than the analyst estimate of $1.06. Revenue for the quarter came in at $745.3 million versus the consensus estimate of $693.54 million.

Our outperformance in 2020 capped off a breakthrough year for Horizon, said Tim Walbert, chairman, president and chief executive officer, Horizon. The launch of TEPEZZA, one of the most successful rare disease medicine launches... More